Clinical Trials Available
To view a list of available clinical trials, select a type of cancer below. You will get a general overview of the trial, the trial number, and a link to clinicaltrials.gov for the most complete information.
Our collaboration with Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, offers our patients early access to the latest in leading-edge treatments without having to leave the Twin Cities region.
Request Clinical Trial Information
Breast Cancer: FLEX Registry
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry)
Learn More
Breast Cancer: GLSI-21-01
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy
Learn More
Breast Cancer: J2J-MC-JZLH
A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
Learn More
Breast Cancer: GS-US-595-6184
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Learn More
Breast Cancer: D926QC00001
A Phase III, Open-Label, Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Learn More
Breast Cancer: D7630C00001
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Learn More
Breast Cancer: JZP598-303
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment
Learn More
Biliary Cancer: JZP598-302
An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer
Learn More
Cervical Cancer: GOG-3043
A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer
Learn More
Endometrial Cancer: PRO1184-001
Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors
Learn More
Fallopian Tube Cancer: GOG-3078
Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab
Learn More
Fallopian Tube Cancer: GOG-3086
A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab tazevibulin (STRO-002) versus Investigator's Choice (IC) Chemotherapy in Women with Relapsed Platinum resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha
Learn More
Lung Cancer: 22285
Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Longitudinal Prospective RWE Study (MYLUNG Consortium Part 3: Observational Study)
Learn More
Lung Cancer: SGNB6A-002
A randomized, phase 3, open-label study to evaluate sigvotatug vedotin compared with docetaxel in adult participants with previously treated non-small cell lung cancer
Learn More
Lung Cancer: PUMA-ALI-4201
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Learn More
Melanoma Cancer: IDE196-002
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Learn More
Ovarian Cancer: GOG-3043
A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer
Learn More
Ovarian Cancer: GOG-3086
A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab tazevibulin (STRO-002) versus Investigator's Choice (IC) Chemotherapy in Women with Relapsed Platinum resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha
Learn More
Ovarian Cancer: VS-6766-301
A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer
Learn More
Ovarian Cancer: PRO1184-001
Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors
Learn More
Peritoneal Cancer: GOG-3078
Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab
Learn More
Peritoneal Cancer: GOG-3086
A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab tazevibulin (STRO-002) versus Investigator's Choice (IC) Chemotherapy in Women with Relapsed Platinum resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha
Learn More
Solid Tumor: PRO1184-001
Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors
Learn More
Solid Tumor: ART0380C001
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors
Learn More